New drug aims to free MDS patients from frequent blood transfusions
NCT ID NCT07319845
Summary
This study is testing an investigational drug called TAK-226 to see if it can help Japanese adults with a lower-risk type of bone marrow disorder called myelodysplastic syndromes (MDS). The main goal is to see if the drug can reduce or eliminate the need for regular red blood cell transfusions, which many patients require to manage severe anemia. Participants will receive the drug and be closely monitored for safety and effectiveness over several years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.